First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

BACKGROUND: The [(177)Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostatin antagonist, [(177)Lu]Lu-DOTA-JR11, that demonstrated b...

Descripción completa

Detalles Bibliográficos
Autores principales: Handula, Maryana, Beekman, Savanne, Konijnenberg, Mark, Stuurman, Debra, de Ridder, Corrina, Bruchertseifer, Frank, Morgenstern, Alfred, Denkova, Antonia, de Blois, Erik, Seimbille, Yann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313624/
https://www.ncbi.nlm.nih.gov/pubmed/37389800
http://dx.doi.org/10.1186/s41181-023-00197-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313624/
https://www.ncbi.nlm.nih.gov/pubmed/37389800
http://dx.doi.org/10.1186/s41181-023-00197-0

Ejemplares similares